MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

Abstract Background Mutant peptides presented by MHC (major histocompatibility complex) Class II in cancer are important targets for cancer immunotherapy. Both animal studies and clinical trials in cancer patients showed that CD4 T cells specific to tumor-derived mutant peptides are essential for th...

Full description

Bibliographic Details
Main Authors: Weijing Cai, Dapeng Zhou, Weibo Wu, Wen Ling Tan, Jiaqian Wang, Caicun Zhou, Yanyan Lou
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Genomics
Subjects:
Lung cancer
Neo-antigen
Cancer vaccine
PD1 checkpoint blocking antibody
Online Access:http://link.springer.com/article/10.1186/s12864-018-4958-5

Internet

http://link.springer.com/article/10.1186/s12864-018-4958-5

Similar Items